| Variables | Results |
|---|---|
| Age (Month) | 10.90 ± 2.48 |
| Age groups | |
| ≥12 years (%) | 22 (55%) |
| <12 years (%) | 18 (45%) |
| Gender | |
| Boys (%) | 24 (60%) |
| Girls (%) | 16 (40%) |
| Headache zone | |
| Vertex (%) | 7 (17.5%) |
| Occipital (%) | 8 (20%) |
| Frontal (%) | 18 (45%) |
| Temporal (%) | 7 (17.5%) |
| Unilateral/bilateral | |
| Unilateral (%) | 8 (20%) |
| Bilateral (%) | 32 (80%) |
| Disease severity | |
| Mild to moderate (%) | 13 (32.5%) |
| Severe (%) | 27 (67.5%) |
| Headache quality | |
| Throbbing (%) | 31 (77.5%) |
| Non-throbbing (%) | 9 (22.5%) |
| Headache coupled with activity | |
| Yes (%) | 27 (67.5%) |
| No (%) | 13 (32.5%) |
| Motion sickness | |
| Yes (%) | 13 (32.5%) |
| No (%) | 27 (67.5%) |
| Attacks before beginning prophylaxis | |
| <1 week | 22 (55%) |
| 1 week to 1 month | 15 (37.5%) |
| 1 month to 3 month | 3 (7.5%) |
| >3 month | 0 |
| Attacks after beginning prophylaxis | |
| <1 week | 1 (2.5%) |
| 1 week to 1 month | 15 (37.5%) |
| 1 month to 3 month | 18 (45%) |
| >3 month | 6 (15%) |